M&A Deal Summary |
|
|---|---|
| Date | 2025-02-04 |
| Target | Pharmaceutics International |
| Sector | Life Science |
| Buyer(s) | Jabil |
| Sellers(s) |
Signet Healthcare Partners
Athyrium Capital Management Hildred Capital Partners |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Manufacturing |
| Employees | 138,000 |
| Revenue | 28.9B USD (2024) |
Jabil is an electronic solutions company providing comprehensive electronics design, manufacturing and product management services to global electronics and technology companies. Jabil was founded in 1996 and is based in St. Petersburg, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 11 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 11 of 11 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 7 of 7 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-11-06 |
Retronix
Coatbridge, United Kingdom Retronix is a provider of reclamation and refurbishment services for electronic components. Retronix is based in Coatbridge, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-03-04 |
Jabil - Radio Portfolio IPR and R&D Team
St. Petersburg, Florida, United States Jabil's Radio Portfolio, IPR, and R&D Team provide a range of single, dual, and triple-band macro radios, designed to support global operators across multiple spectrum bands. |
Sell | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1998 |
| PE ASSETS | 600M USD |
| Size | Middle-Market |
| Type | Sector Focused |
Signet Healthcare Partners is a growth capital firm focused on the healthcare sector. Specific areas of interest include specialty pharmaceuticals, pharmaceutical services, medical devices, and diagnostics. Signet will consider opportunities throughout North America and Europe and looks to commit $10 to $50 million per transaction. Signet Healthcare Partners was established in 1998 and is headquartered in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-08-22 |
Paragonix Technologies
Waltham, Massachusetts, United States Paragonix Technologies is a developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation. Paragonix Technologies provides Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients. Paragonix Technologies is based in Waltham, Massachusetts. |
Sell | - |
| Category | Asset Manager |
|---|---|
| Founded | 2008 |
| PE ASSETS | 3.7B USD |
| Size | Large |
| Type | Sector Focused |
Athyrium Capital Management is a large asset manager focused on the healthcare sector. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium Capital was established in 2008 and is headquartered in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 10 |
| Sector: Life Science M&A | 6 of 6 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 9 of 9 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-12 |
Alcresta Therapeutics
Newton, Massachusetts, United States Alcresta Therapeutics is a specialty pharmaceutical company focusing on discovering and developing a new generation of enzyme-based products that improve digestion and absorption of important nutrients. The company's lead program is a point-of-care, enzyme-based product that improves the bioavailability of long-chain fatty acids (such as DHA, EPA, and AA) for patients with impaired pancreatic output. Compromised pancreatic function is a complication of many diseases such as cystic fibrosis, chronic pancreatitis, and cancer as well as developmental immaturity, and Alcresta's products are aimed at meeting the nutritional needs of these patients. Alcresta Therapeutics was formed in 2011 and is based in Newton, Massachusetts. |
Sell | - |
Hildred Capital Partners is a family backed investment firm focused on active and passive investments across a range of securities. The Firm does not have any geographic preferences and will consider both equity and debt investing. Hildred Capital Partners was formed in 2014 and is headquartered in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-11-30 |
GlaxoSmithKline - Consumer Healthcare Portfolio
Brentford, United Kingdom GlaxoSmithKline plc - Consumer Healthcare Portfolio has long been regarded as high quality, safe and effective, maintaining a quality image and loyal base of consumers. OTC medications allow practitioners and their patients the ability to access therapeutic products while reducing the burden of prescription drug costs on the healthcare system. The products expand Crown Laboratories’ consumer portfolio by adding #1 in category brands that treat multiple conditions. The acquired portfolio includes PanOxyl®: #1 Dermatologist recommended daily acne wash Sarna®: #1 Dermatology recommended anti-itch lotion Zeasorb®: #1 Dermatologist recommended anti-fungal and prevention product Desenex®: Anti-fungal powder for athlete’s foot Mineral Ice®: Leading pain-relieving gel. |
Buy | - |
